secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001558370-24-004325
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO reports FY23 net loss $42.2M; Phase 2b PCED trial data expected YE 2024
--------------------------------------------------------------------------------

- Q4 2023 net loss $8.6M ($3.18/sh) vs $12.8M ($7.97/sh) in Q4 2022.
- FY 2023 net loss $42.2M ($17.35/sh) vs $44.8M ($29.48/sh) in FY 2022.
- Cash $50.9M at Dec 31, 2023; with $8.6M Mar 2024 placement, runway into Q3 2025.
- R&D expenses Q4 $4.7M (up from $3.3M) driven by KPI-012 development costs.
- KPI-012 Phase 2b CHASE trial for PCED enrolling; topline data targeted by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837024004325/0001558370-24-004325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837024004325/kala-20240329x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-004325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer